Benefits of solid organ transplantation in end stage organ diseases are indisputable. Malignancy is a feared complication of solid organ transplantation and is a leading cause of mortality in patients with organ transplantation. Iatrogenic immunosuppression to prevent graft rejection plays a crucial role in the cancer development in solid organ transplant recipients. Chronic exposure to immunosuppression increases the malignancy burden through deregulation of host immune defense mechanisms and unchecked proliferation of oncogenic viruses and malignancies associated with these viruses. Vigorous screening of candidates undergoing transplant evaluation for malignancies, careful assessment of donors, and vigilant monitoring of transplant recipients are necessary to prevent, detect, and manage this life-threatening complication.
CITATION STYLE
Munagala, M., & Phancao, A. (2022). Malignancy: An Adverse Effect of Immunosuppression. In Handbook of Experimental Pharmacology (Vol. 272, pp. 315–335). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/164_2021_554
Mendeley helps you to discover research relevant for your work.